1. In this randomized, placebo controlled study of HER2-positive breast cancer patients receiving trastuzumab, use of preventative lisinopril or carvedilol did not significantly reduce cardiotoxicity compared to placebo.
2. For patients undergoing therapy with trastuzumab combined with anthracyclines, use of either carvedilol or lisinopril was associated with a reduced risk...